Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) is a type of B-cell non-Hodgkin’s lymphoma and represents the most common form of leukemia in adults. The R/R CLL treatment landscape has witnessed a paradigm shift with the introduction of targeted therapies and is now dominated by small-molecule BTK inhibitors (Imbruvica, Calquence, and Brukinsa) and the BCL-2 inhibitor Venclexta / Venclyxto. Nevertheless, the prognosis of patients with high-risk features, including TP53 mutations and/or 17p deletions, remains poor, reflecting a significant area of unmet need. Furthermore, acquired resistance to these targeted therapies creates an additional need for novel treatments and optimization of treatment sequencing.
Questions answered
What are the most important factors driving hematologist-oncologists’ prescribing decisions for R/R CLL?How do current therapies, such as Calquence and Brukinsa, perform on key clinical attributes for this patient population?What are the prevailing areas of unmet need in this setting?What trade-offs in terms of different clinical attributes and cost would hematologist-oncologists be willing to make for a hypothetical new therapy for R/R CLL?Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 32 European hematologist-oncologists fielded in April 2024
Key drugs: Rituxan, Imbruvica, Calquence, Brukinsa, Zydelig, Copiktra, and Venclexta / Venclyxto
Product description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Key feature
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.